Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action.
Endocrine Unit, Department of Medical Sciences, University of Milan, Italy. mario@mariosalvinet.it
Mario
M
Salvi
Guia
G
Vannucchi
Nicola
N
Currò
Martino
M
Introna
Stefania
S
Rossi
Paola
P
Bonara
Danila
D
Covelli
Davide
D
Dazzi
Claudio
C
Guastella
Lorenzo
L
Pignataro
Roberto
R
Ratiglia
Josée
J
Golay
Paolo
P
Beck-Peccoz
D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000009:adverse effects; D018941:Antigens, CD19 / Q000378:metabolism; D018951:Antigens, CD20 / Q000378:metabolism; D001402:B-Lymphocytes / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D049970:Graves Ophthalmopathy / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects; D008212:Lymphocyte Depletion; D008264:Macrophages / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009916:Orbital Diseases / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D018941:Antigens, CD19; D018951:Antigens, CD20; D007155:Immunologic Factors; D000069283:Rituximab